Skip to Main Content
Lantern_Icon_blue
Lantern by Labaton
Link_Arrow
ClientConnect_Icon_blue
Client Connect
Link_Arrow
Labaton Logo
  • The Firm
  • Practices
  • Our Team
  • Cases
  • News & Insights
  • Client Services
  • Careers
Contact Us
Established 1963

Back to Resolved Cases
Practice Area: Securities Litigation
Updated: December 23, 2020

In re Dr. Reddy's Laboratories Limited Securities Litigation

Case Materials

Amended Complaint
Claim Form
Notice
Preliminary Approval Order
Stipulation of Settlement
Lead Plaintiff’s Motion for Final Approval of Class Action Settlement and Plan of Allocation
Memorandum of Law ISO Lead Plaintiff’s Motion for Final Approval of Class Action Settlement and Plan of Allocation
Lead Counsel’s Motion for an Award of Attorneys’ Fees and Expenses
Memorandum of Law ISO Lead Counsel’s Motion for an Award of Attorneys’ Fees and Expenses
Declaration of Michael H. Rogers and Exhibits 1-7
Final Order and Judgement
Order Approving Plan of Allocation
Order Awarding Attorneys' Fees and Expenses

Labaton Keller Sucharow was appointed lead counsel on November 21, 2017, in this securities class action against Dr. Reddy’s Laboratories, a multinational pharmaceutical company based in Hyderabad, India.  On March 5, 2018, the plaintiffs filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the SEC on behalf of entities who purchased or otherwise acquired publicly traded securities of Dr. Reddy’s Laboratories, Ltd. from November 27, 2014, through September 15, 2017.  Specifically, Dr. Reddy’s misled investors about having robust quality processes and systems in place at its manufacturing facilities.  Dr. Reddy’s shares dropped after a series of disclosures by the FDA and other regulators revealed that conditions at three key Indian manufacturing facilities violated FDA regulations, causing the company to delay production of a key product and miss earnings.  The court heard oral argument on Defendants’ motion to dismiss on August 8, 2018.  On March 21, 2019, the court granted in part and denied in part Defendants' motion to dismiss.

Discovery then commenced, and the Parties served their respective Fed. R. Civ. P. 26 initial disclosures, requests for the production of documents, and responses and objections to the requests for production of documents.  In response, Defendants produced 20,277 records, comprised of 132,244 pages of documents.

On May 15, 2020, the Parties executed the Stipulation and Agreement of Settlement.

The case is In re Dr. Reddy’s Laboratories Limited Securities Litigation, No. 17-cv-06436 (D. N.J.). Labaton Keller Sucharow represents lead plaintiff Public Employees’ Retirement System of Mississippi.

Submit Claim Form

If you purchased or otherwise Dr. Reddy’s American Depositary Shares (“ADSs”) on the New York Stock Exchange (“NYSE”) during the period from November 27, 2014 through September 15, 2017, inclusive (the “Class Period”), you may be entitled to a payment from a class action settlement.  To be eligible for a payment, you must submit a Claim Form to the Claims Administrator by September 22, 2020.

Settlement Hearing

The Court held the Settlement Hearing telephonically on December 23, 2020, and approved the Settlement, the Plan of Allocation, and the request for attorneys’ fees and expenses.

If you have questions about the Settlement, please contact Labaton Keller Sucharow at settlementquestions@labaton.com or 1-888-219-6877, or contact the Claims Administrator, at (855) 917-3520.

Additional information about the Settlement can also be found at: www.DrReddysSecuritiesSettlement.com.

logo

Our Locations

New York

140 Broadway
New York, NY 10005
Tel: +1 212.907.0700

Delaware

222 Delaware Avenue, Suite 1510
Wilmington, DE 19801
Tel: +1 302.573.2540

London

1 King William Street
London, EC4N 7AF United Kingdom
Tel: +44 20 3582 0981

Washington, D.C.

1050 Connecticut Avenue NW, Suite 500
Washington, D.C. 20036
Tel: +1 202.772.1881

Useful Links

  • Practices
  • Cases
  • News & Insights
  • Client Services
  • Contact

The Firm

  • Our Team
  • Our Story
  • Awards & Accolades
  • Offices
  • Social Commitment
  • Careers for Attorneys
  • Careers for Business Professionals
  • Attorney Development

Stay Connected

fbfb
Facebook
Xx
Twitter / X
inin
LinkedIn
Footer_Graphic
© Labaton Keller Sucharow LLP All Rights Reserved 2026
Attorney Advertising DisclaimerPrivacy PolicyCookie PolicyCalifornia Privacy Policy and Notice of Collection of Personal InformationTransparency in Coverage Rule